Homepage > Company > Media > Pharma News > 2020 > Relief Therapeutics announces supply deals while awaiting COVID-19 trial data

Relief Therapeutics announces supply deals while awaiting COVID-19 trial data

ZURICH (Reuters) - Switzerland’s Relief Therapeutics and U.S. partner NeuroRx said on Wednesday they struck deals with Bachem and Nephron Pharmaceuticals to supply and make a 50-year-old drug, aviptadil, that is in clinical trials against COVID-19.

Relief and NeuroRx said the pact with Switzerland’s Bachem, to supply peptides, and U.S. generics maker Nephron, to manufacture aviptadil, also being called RLF-100 by the companies, is aimed at having supplies sufficient to treat 1 million patients, should the drug prove effective in the studies.

SEPTEMBER 30, 2020

https://www.reuters.com/

Read also

Merck KGaA

Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership

FDA Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC

ALS oral therapy

ALS oral therapy slows disease progression in preclinical testing

Alvotech and Advanz

Alvotech and Advanz announce EC approval for Gobivaz biosimilar